Abstract:
Objective This study aims to explore the prognostic role of mutation subtypes of Kirsten rat sarcoma viral oncogene （
KRAS） in advanced lung adenocarcinoma and their relation with expression level of programmed death ligand 1 （PD-L1）.
Methods We retrospectively collected tumor specimens of 91 advanced
KRAS-mutant lung adenocarcinoma. Next-generation sequencing was employed to detect the genomic alterations of cancer related genes and immunohistochemistry was applied to determine the expression level of PD-L1. Clinical and survival data were collected for Kaplan-Meier analysis.
Result KRAS G12C, G12D, G12V and other mutations made up 33.0%, 20.9%, 15.4% and 30.8% of all patients respectively. Positivity of expression of PD-L1 ≥1% were 86.7%, 44.4% and 50.0% respectively in
KRAS G12C, G12D and G12V subgroups. Positive ratio of PD-L1 ≥1% in
KRAS G12C is higher than
KRAS G12D tumors （
P=0.028）.
Conclusion Mutation subtypes of
KRAS were not prognostic of survival in
KRAS mutant patients with NSCLC. Yet expression of PD-L1 was higher in
KRAS G12C versus other mutation subtypes, which needs further investigation for its potential predictive role for immune therapy.
下载: